38 related articles for article (PubMed ID: 3971358)
1. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
Reilly KM; Kisor DF
Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
[TBL] [Abstract][Full Text] [Related]
2. Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
Yanagi M; Mori M; Honda M; Mitani Y; Seki M; Fukuoka K; Oshima K; Arakawa Y; Koh K
Int J Hematol; 2024 Mar; 119(3):327-333. PubMed ID: 38302839
[TBL] [Abstract][Full Text] [Related]
3. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
Shimony S; DeAngelo DJ; Luskin MR
Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
[TBL] [Abstract][Full Text] [Related]
4. The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.
Levi J; Song H
Front Immunol; 2022; 13():1113924. PubMed ID: 36700226
[TBL] [Abstract][Full Text] [Related]
5. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
Liu X; Jiang Y; Nowak B; Ichikawa S; Ohtawa M; Matsuda A; Plunkett W
Cancer Chemother Pharmacol; 2020 Apr; 85(4):661-672. PubMed ID: 32072218
[TBL] [Abstract][Full Text] [Related]
6. Relapsed T Cell ALL: Current Approaches and New Directions.
McMahon CM; Luger SM
Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
[TBL] [Abstract][Full Text] [Related]
7. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant.
Ronald JA; Kim BS; Gowrishankar G; Namavari M; Alam IS; D'Souza A; Nishikii H; Chuang HY; Ilovich O; Lin CF; Reeves R; Shuhendler A; Hoehne A; Chan CT; Baker J; Yaghoubi SS; VanBrocklin HF; Hawkins R; Franc BL; Jivan S; Slater JB; Verdin EF; Gao KT; Benjamin J; Negrin R; Gambhir SS
Cancer Res; 2017 Jun; 77(11):2893-2902. PubMed ID: 28572504
[TBL] [Abstract][Full Text] [Related]
8. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
9. The role of transporters in the toxicity of nucleoside and nucleotide analogs.
Koczor CA; Torres RA; Lewis W
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):665-76. PubMed ID: 22509856
[TBL] [Abstract][Full Text] [Related]
10. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.
Parker WB
Chem Rev; 2009 Jul; 109(7):2880-93. PubMed ID: 19476376
[No Abstract] [Full Text] [Related]
11. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.
DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA
Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466
[TBL] [Abstract][Full Text] [Related]
12. Promising approaches in acute leukemia.
Cortes J; Kantarjian HM
Invest New Drugs; 2000 Feb; 18(1):57-82. PubMed ID: 10830141
[TBL] [Abstract][Full Text] [Related]
13. Deoxyguanosine-resistant leukemia L1210 cells. Loss of specific deoxyribonucleoside kinase activity.
Cory AH; Shibley IA; Chalovich JM; Cory JG
J Biol Chem; 1993 Jan; 268(1):405-9. PubMed ID: 8380161
[TBL] [Abstract][Full Text] [Related]
14. Membrane transport and the antineoplastic action of nucleoside analogues.
Sirotnak FM; Barrueco JR
Cancer Metastasis Rev; 1987; 6(4):459-80. PubMed ID: 3327628
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
[TBL] [Abstract][Full Text] [Related]
16. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
Verhoef V; Fridland A
Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
[TBL] [Abstract][Full Text] [Related]
17. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
Shewach DS; Mitchell BS
Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
[TBL] [Abstract][Full Text] [Related]
18. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.
Owens JK; Shewach DS; Ullman B; Mitchell BS
Cancer Res; 1992 May; 52(9):2389-93. PubMed ID: 1568208
[TBL] [Abstract][Full Text] [Related]
19. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
